Scientific Advisory Board
Our advisors are available to offer strategic and practical recommendations to our clients as part of the initial briefing stage of the search process. ​They are utilized for their advanced subject matter knowledge and professional networks to help calibrate the sourcing efforts and advise on organizational, technical, regulatory and scientific matters critical to finding and securing the right candidate.
Chief Development Officer & SAB Chair
Gavin Corcoran, MD FACP
As Chief Development Officer (CDO) at Formation Bio, Gavin is an experienced drug development innovator, strategist, and business builder. With previous roles including Chief R&D Officer at Axovant Gene Therapies and Chief Medical Officer at Allergan, his expertise spans therapeutic areas like CNS, CV, Dermatology, and Respiratory, boasting over 20 approvals worldwide. Gavin is Board Certified in Infectious diseases and Internal Medicine and is an enthusiastic integrator of AI into Drug Development.
Professor of Research, Genetic Medicine
Dolan Sondhi, Ph.D
Dr. Sondhi is a highly accomplished research scientist with over two decades of experience in all aspects of clinical translation of AAV gene therapies for genetic disorders, focusing on CNS and metabolic diseases. She is a Professor of Research in Genetic Medicine, Associate Director of the Gene Therapy Core Facility at Weill Cornell Medicine and serves on corporate and scientific advisory boards. Dr. Sondhi holds a Ph.D. from Brown University.
Strategy and Program & Portfolio Management
Roberta Duncan, MBA
Roberta Duncan, Chief Stratergy Officer at Arcturus Tx and Vice Chair of the Alliance for mRNA Medicines, has over 25 years in biopharma. Specializing in vaccine and drug development, she's skilled in asset strategy, R&D, strategic planning, and diverse therapeutic product development. Her experience spans CSL, Shire, Trevi Therapeutics, BMS, Kendle International, and Eli Lilly. Duncan holds a BA in Biochemistry and a dual MBA.
CEO & Venture Partner
Kent Rogers, MBA
Kent Rogers is the CEO of EveryONE Medicines, a Venture Partner at ARCH, and serves on the board of SlateRx. With over 30 years in product commercialization, supply chain logistics, pricing, market access, and growth strategies, he is a seasoned executive. Previously, he was the CCO of EQRx, leading pre-commercialization strategies. At OptumRx, he managed $40 billion in annual rebate agreements and over $16 billion in specialty med procurement for Optum Specialty Pharmacy. Kent also held leadership roles at Acorda Therapeutics, Schering-Plough, and Merck. He has served in multiple advisory roles for pharmaceutical firms, payer organizations and the National Business Group on Health. He has a B.S. from Indiana University and an M.B.A. from Emory University.
Translational Medicine & Clinical Development
Erika De Boever, PhD
Erika De Boever, has over 20 years in the pharmaceutical and biotech sectors, specializes in gene therapies and has held leadership roles at uPenn, Sio Gene Therapies, and GSK. Notably, she contributed to the approval of Strimvelis for ADASCID at GSK. Her expertise in gene therapy and rare diseases is crucial for Intelisci, enhancing client support for clinical transitions.
CMC & Manufacturing
Kirsten Pier, MBA
Kirsten Pier, holds 18 years in CMC, specializes in process development and manufacturing for clinical and commercial sectors. At TKD Solutions, she leads operations, offering expertise in biotech products. Her background includes senior roles at Sio Gene Therapies, Bluebird Bio, Shire, and Amgen, covering research to commercial phase development. Her insights significantly enhance our CMC candidate delivery.
Immunology/Inflammatory Product Development
Neil Wishart, PhD
Neil Wishart, is a Global Biopharma Executive with three decades of exceptional leadership. Known for pioneering approaches in I&I, he has played pivotal roles at AbbVie Bioresearch Center, contributing to groundbreaking immunology therapies like RinvoqTM (upadacitinib). Neil led the development of immunology and inflammation programs at EQRx, which successfully went public during his tenure via SPAC. Neil is currently VP Clinical Strategy at Celldex.
R&D Leader. Platform & Asset Strategy
Sara Cortese, PhD
Sara Cortese is a pharmaceutical R&D leader with 20 years’ experience in the discovery of clinical candidates across multiple diseases. As president of SwipeRightBio-tech, she advises startups, biotechs, and VCs in asset and platform strategies. As a Managing Director at Accenture, she built strategies enabling AI in R&D, including an AI-driven personalized medicine solution. Her expertise from leadership roles at GSK, Roche and Accenture are crucial for Intelisci’s client support for commercializing Biotech innovation.
Commercial & Business Development
Rod Cameron, PHD
Rod, founder of CamPharm Consulting Group, is a leading expert in outsourcing, technology transfer, and business strategy. His 22-year career includes significant roles at BMS, Sanofi Pasteur, and Merck, focusing on strategic licensing in oncology and immunology. He specializes in managing large-scale outsourcing and capital projects. Rod holds two Chemistry PhDs from the University of Cambridge.
Lipid Nanoparticles & Parenteral Drug Expert
Alexander Aust, MA, MBA
Alex, a peerless expert in cell and gene therapy, has extensive experience in commercializing and manufacturing complex drug products, including lipid nanoparticles. Alex is founder of Aust Business Solutions and holds an MBA from Ball State and an MS in Molecular and Cellular Biology from Purdue University, and previously led Business Development at Exelead Biopharma.
Advanced Clinical Stage Oncology Strategy
Rob Drury-Dryden, MBA
Rob, founder of Precision Biopharma Consultancy, specializes in oncology drug development, with a focus on biomarker-led therapies. His 17-year career spans AstraZeneca (Lyparza), Merck Serono (Erbitux), and Janssen (Balversa, Zytiga, Erleada). Rob holds an MSc in Biochemistry and an MBA, leading with innovation and focusing on organizational design and charity through sports.